about
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot StudyPlatelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper.Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses.Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.Relation of Neutrophil to Lymphocyte Ratio With Periprocedural Myocardial Damage in Patients Undergoing Elective Percutaneous Coronary Intervention.Comparison among patients≥75 years having percutaneous coronary angioplasty using drug-eluting stents versus bare metal stents.Thrombus aspiration in primary percutaneous coronary intervention: still a valid option with improved technique in selected patients!Idiopathic sensorineural hearing loss is associated with endothelial dysfunction.Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.Effective radiation dose, time, and contrast medium to measure fractional flow reserve.Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention.High cholesterol levels are associated with coronary microvascular dysfunction.Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus.Letter by Mangiacapra and Barbato regarding article, "Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease".Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment.Relationship between time of day and periprocedural myocardial infarction after elective angioplasty.Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).Quantitative angiography and optical coherence tomography for the functional assessment of nonobstructive coronary stenoses: comparison with fractional flow reserve.Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention.A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for OutcomePoint-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-PlateleLack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel.Long-term clinical outcome after fractional flow reserve- versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts.Functional SYNTAX score for risk assessment in multivessel coronary artery disease.Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease.Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX.Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis.Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease.α2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant.Correlation between serum uric acid levels and residual platelet reactivity in patients undergoing PCI.NT-proANP circulating level is a prognostic marker in stable ischemic heart disease.Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary InterventionEffects of Prasugrel Versus Clopidogrel on Coronary Microvascular Function in Patients Undergoing Elective PCIEfficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8Intracoronary EnalaPrilat to Reduce MICROvascular Damage During Percutaneous Coronary Intervention (ProMicro) study
P50
Q35610354-316B53F9-F292-4099-8C7D-53FD63D83AB2Q35931098-4F948B46-E075-448D-ADCF-DE10A1F9D21CQ38229559-4F77299B-CFD2-4CE8-920A-FFB7106F5581Q39228073-8064C8BC-3FE7-4F9E-9F53-7C88A8FE61B1Q39493684-43C77F79-A69F-4055-91E0-30C8157DE49AQ40625349-FF7C98B0-91D6-47D7-A286-CB9B08336FABQ41223734-EAF011DD-F7AE-4ECC-B4B9-B6496B10FDAFQ42333640-8361D1FE-7638-4D61-9274-031806B15793Q42343800-B40112EB-3235-4CB0-9AD5-22A0522BAFDCQ42466382-C562E377-5C2F-4DB8-979A-B9EEA531FBAEQ42844498-55F81C1D-F74E-41E7-A893-6BCCF83A3B1BQ42932160-C286714D-4FFE-461D-8D3C-36342DA20428Q42932245-D868A6EF-32D6-4216-9505-9F1F8B58D88BQ43124898-25E2074C-F6FD-4645-AA33-6567111D3F19Q43175056-10A96101-099E-48E4-8542-F505ED9F2110Q43611554-4B043776-BAF7-4FAA-A7C7-72702684E838Q43612447-B9CC1D03-2288-4C21-AA76-B41A39F08684Q43933805-E1A01B46-E11E-4784-836C-B41357C6FC9AQ44219411-DB029DC3-5EDD-4B39-A155-4B363F0D8200Q44478983-04400C83-9024-4189-82BA-D41138819816Q44536128-2EC112A1-359D-47B8-994F-81960C06F231Q44873936-0F343AF6-F080-400C-828F-BBF25351CA9AQ45839482-50655C58-DEE4-47AE-A483-D72332E3C385Q45882558-D0582D04-4643-4878-B0D8-CFB831343C0EQ46062168-B3E4A6B4-3248-4E76-B104-04B3C41DA35AQ46119763-930445BB-E72B-417F-8816-C72C553B4F8AQ46211908-9407DAEC-4309-4D0A-85E8-B8A85FADC9E5Q46506609-C687F83B-0880-4ACF-9EA9-F29286EDDCD3Q46841316-D7F53AD8-33D7-4DF2-AF53-3F6961617E45Q47781970-BDB0B24E-F469-4C90-BA59-1C2F77E11A62Q47862169-1B78316D-9E17-4341-8279-4B04BA7F6586Q49948271-C7D1F678-FD1E-4C4C-A918-E68F223F5B17Q50997002-3C9C7731-4BA6-4D88-9D2E-38EB61ACB750Q53058436-C8D55479-039B-42F9-A404-13CFB641A642Q54344168-CCB2ADB1-BBCC-4EC3-88EB-1BBDBADCB6A7Q55055397-86B0CB78-4C8C-4309-AECB-1BD71228703AQ57056940-6B7BF898-12CB-4629-8628-A7DA4784890BQ57096265-DDD03309-64C2-4B22-A439-0085C6B1DCC9Q57097475-95B70DBE-C903-40ED-B880-172C5B44BA7AQ57097574-8855F4A5-32DC-492F-AEB9-5139723186C5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabio Mangiacapra
@ast
Fabio Mangiacapra
@en
Fabio Mangiacapra
@es
Fabio Mangiacapra
@nl
Fabio Mangiacapra
@sl
type
label
Fabio Mangiacapra
@ast
Fabio Mangiacapra
@en
Fabio Mangiacapra
@es
Fabio Mangiacapra
@nl
Fabio Mangiacapra
@sl
prefLabel
Fabio Mangiacapra
@ast
Fabio Mangiacapra
@en
Fabio Mangiacapra
@es
Fabio Mangiacapra
@nl
Fabio Mangiacapra
@sl
P106
P1153
24780790600
P21
P31
P496
0000-0002-3505-0716